title: A multicenter phase II study of local radiation therapy for stage IEA mucosa-associated lymphoid tissue lymphomas: a preliminary report from the Japan Radiation Oncology Group (JAROG).
abstract: OBJECTIVE
  The aim of this study was to evaluate the efficacy and toxicity of moderate dose radiation therapy (RT) for mucosa-associated lymphoid tissue (MALT) lymphoma in a prospective multicenter phase II trial.
  
  
  METHODS
  The subjects in this study were 37 patients with MALT lymphoma between April 2002 and November 2004. There were 16 male and 21 female patients, ranging in age from 24 to 82 years, with a median of 56 years. The primary tumor originated in the orbit in 24 patients, in the thyroid and salivary gland in 4 patients each, and 5 in the others. The median tumor dose was 30.6 Gy (range, 30.6-39.6 Gy), depending on the primary site and maximal tumor diameter. The median follow-up was 37.3 months.
  
  
  RESULTS
  Complete remission (CR) or CR/unconfirmed was achieved in 34 patients (92%). The 3-year overall survival, progression-free survival, and local control probability were 100%, 91.9%, and 97.3%, respectively. Thirteen patients experienced Grade 1 acute toxicities including dermatitis, mucositis, and conjunctivitis. One patient developed Grade 2 taste loss. Regarding late toxicities, Grade 2 reactions including hypothyroidism, and radiation pneumonitis were observed in three patients, and Grade 3 cataract was seen in three patients.
  
  
  CONCLUSIONS
  This prospective phase II study demonstrated that moderate dose RT was highly effective in achieving local control with acceptable morbidity in 37 patients with MALT lymphoma.
authors.affiliation: Department of Radiology, Chiba University Hospital, Chiba, Japan. isobeko@ho.chiba-u.ac.jp
authors.forename: Koichi
authors.initials: K
authors.lastname: Isobe
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Kagami
authors.forename: Keiko
authors.initials: K
authors.lastname: Higuchi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kodaira
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Hasegawa
authors.forename: Naoto
authors.initials: N
authors.lastname: Shikama
authors.forename: Masanori
authors.initials: M
authors.lastname: Nakazawa
authors.forename: Ichiro
authors.initials: I
authors.lastname: Fukuda
authors.forename: Keiji
authors.initials: K
authors.lastname: Nihei
authors.forename: Kana
authors.initials: K
authors.lastname: Ito
authors.forename: Teruki
authors.initials: T
authors.lastname: Teshima
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Matsuno
authors.forename: Masahiko
authors.initials: M
authors.lastname: Oguchi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009918:Orbital Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy; D011446:Prospective Studies; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D012074:Remission Induction; D012468:Salivary Gland Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy; D013964:Thyroid Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy